Equashield
Closed-system Transfer Devices for Safe Handling of Hazardous Drugs
Company Overview
Snapshot
Founded in April 2009 by Erik Shem Tov and Marino Kriheli, Equashield operates with 51–200 employees. The company was acquired by Nordic Capital in October 2022.
Business overview
Equashield Medical develops advanced, automated solutions designed to protect healthcare workers and facilities from hazardous drug exposure and contamination. The company's core offerings include Equashield CSTD, an airtight closed-system drug-transfer device, and Equashield Pro, an automatic compounding system utilizing advanced image-processing algorithms. Equashield serves the healthcare industry, focusing on sectors such as medical devices and medical treatment & therapeutics, to enhance safety and efficiency in drug handling.
Strategic signal
In October 2022, Equashield was acquired by Nordic Capital, indicating a significant strategic validation of its technology and market position. This acquisition signals strong investor confidence in the company's closed-system transfer devices for hazardous drugs and suggests potential for expanded market reach and continued innovation under new ownership.
Log in to access full profile ›Company Intelligence Q&A
- When was Equashield founded?
- Equashield was founded in April 2009.
- Who are the founders of Equashield?
- Equashield was co-founded by Erik Shem Tov and Marino Kriheli.
- What is Equashield's primary business?
- Equashield develops closed-system transfer devices and automated compounding systems to protect healthcare workers from hazardous drug exposure.
- What is the Equashield CSTD?
- The Equashield CSTD is an airtight closed-system drug-transfer device designed to protect against occupational exposure to hazardous drugs.